SUMMARy
The inflammatory reactions and tissue response after oesophagectomy are leading causes of postoperative morbidity and mortality. We evaluated the effects of intraoperative infusion of prostaglandin E 1 (PGE 1 ) on interleukin-6 (IL-6) levels, (A-a) DO 2 , pulmonary function and complications. This randomised double-blind clinical trial study was performed on patients undergoing transthoracic oesophagectomy due to cancer. Thirty patients were randomly allocated to two groups: the PGE 1 group (infusion of PGE 1 , 20 ng.kg -1 .min -1 ) and a placebo group (infusion of normal saline 0.9%). The infusion was started before induction of anaesthesia and continued until the end of the operation. The groups were comparable in basic characteristics and preoperative pulmonary function. Patients in the PGE 1 group were discharged significantly earlier from the intensive care unit (72±9 vs 83±17 hours) and hospital (13±4 vs 18±8 days) (P=0.04 and 0.03, respectively). The (A-a) DO 2 was significantly less in the PGE 1 group at 12 and 24 hours after the operation (P=0.001, P=0.003, respectively). Postoperatively, IL-6 levels were significantly higher in the placebo group than in the PGE 1 group. There were no differences in the forced expiratory volume in the first second or forced vital capacity. The findings indicate that infusion of PGE 1 attenuates the increase in serum levels of IL-6 in patients undergoing esophagectomy and improves the (A-a) DO 2 . Stays in the intensive care unit and hospital were shorter in the PGE 1 group. However, there were no differences in pulmonary complications. administration of PGE 1 has been shown to attenuate the duration of systemic inflammatory response syndrome 21 . Therefore, PGE 1 might be effective in reducing postoperative mortality and morbidity in patients with oesophageal cancer, especially in terms of pulmonary complications.
As the main goal in this study, we evaluated the effects of intraoperative infusion of PGE 1 on serum levels of IL-6 in patients with transthoracic approach oesophagectomy. Pulmonary functions and complications, duration of intensive care unit (ICU) stay and postoperative hospital admission stay were compared between PGE 1 and control groups.
MATERIALS AnD METHODS
The ethics committee of Tehran University of Medical Sciences approved the study protocol and written informed consent was obtained from each patient. This study was performed from October 2007 to December 2008 in a university referral cancer centre in Tehran (The Cancer Institute, Imam Khomeini Medical Center). All patients scheduled to undergo transthoracic approach oesophagectomy for carcinoma were included. Exclusion criteria were: age >75 years, preoperative chemotherapy or radiotherapy, steroid administration before operation, any antibiotic therapy (except preoperative prophylactic antibiotic administration), oesophageal reconstruction using a segment of jejunum or colon, applying laparoscopy or thoracoscopy, trans-hiatal oesophagectomy, any acute or chronic inflammatory or infectious disease, and any acute or chronic lung disease.
Thirty patients who fulfilled the above criteria were allocated in two equal groups (PGE 1 or placebo group) by block randomisation method. no patient was excluded after randomisation ( Figure 1 ). In the PGE 1 group, infusion of PGE 1 (Prostin VR; Pharmacia & Upjohn, Puurs, Belgium) was started in the operating room just before induction of anaesthesia at a dose of 20 ng.kg -1 .min -1 until the end of the operation and just before transfer to ICU. normal saline 0.9% with the same volume and rate was infused in the placebo group. The patients, anaesthetists and the intensive care physicians were blinded to the intervention group. If the mean arterial blood pressure decreased more than 20% below baseline despite sufficient fluid administration, infusion of dopamine was started at a dose of 5 to 10 μg.kg -1 .min -1 . If dopamine >10 μg.kg -1 .min -1 was needed to maintain the blood pressure in the desired range, the intervention (infusion of PGE 1 or placebo) was halted.
A thoracic epidural catheter was placed for all the patients before induction of anaesthesia. In the sitting position, an epidural catheter was placed with a midline approach through vertebral interspaces between T6-L1. After ruling out the intrathecal catheter placement, an epidural bolus dose of 3 to 4 ml of bupivacaine 0.5% was injected and the catheter was affixed to the skin with a transparent dressing.
General endotracheal anaesthesia for both groups of patients was similar. All patients received midazolam 0.05 mg.kg -1 and sufentanil 0.2 μg.kg -1 five minutes before induction of anaesthesia. Induction of anaesthesia was performed by thiopen- tone sodium 5 mg.kg -1 . Cisatracurium 0.15 mg.kg -1 was used for muscle relaxation. After intubation, general anaesthesia was maintained by isoflurane 1.5 to 2%. Thereafter, the patients received additional cisatracurium and sufentanil as required.
In the postoperative period, patients were mechanically ventilated. They were sedated with an infusion of midazolam intravenously (1 mg.h -1 ). Postoperative analgesia was provided with epidural analgesia with an infusion of 3 to 5 ml.h -1 of bupivacaine 0.125% in combination with fentanyl 1.7 μg.ml -1 . Morphine sulphate (0.05 mg.kg -1 , intramuscularly.) was used for rescue analgesia. The weaning criteria were rapid shallow index <105 (rapid shallow index=RR/TV), P a O 2 /FiO 2 >150, stable haemodynamic variables and acid-base balance.
Basic characteristics, duration of anaesthesia, total surgery and thoracotomy time, blood loss, administered fluids, the lowest systolic and diastolic blood pressures during the operation, preoperative haemoglobin, duration of intubation, ICU and hospital stay, pulmonary function test results including vital capacity (VC) and forced expiratory volume in the first second (FEV 1 ), results of serial serum levels of IL-6, blood gas analysis, any significant pulmonary complications, readmission to ICU (because of respiratory complications) and reintubation were compared between two groups.
Arterial blood samples were obtained before induction of anaesthesia, immediately after the operation and before extubation in ICU to measure IL-6. All the blood samples were collected in three 5 ml sterile syringes. IL-6 was measured by immunoenzymatic assay (BioSourceIL-6-EASIA Kit, BioSource Europe S.A., nivelles, Belgium). Blood gas analysis was performed on the day before the operation, immediately after the operation, on ICU admission and 12 and 24 hours after the operation. Our medical centre is placed at nearly 1160 metres above sea level and barometric pressure is about 660 mmHg. For evaluation of (A-a) DO 2 , the alveolar O 2 tension (P a O 2 ) was calculated using the following formula (P aH2O =47, R=0.8): P a O 2 =FiO 2 ×(660-P aH2O )-P a CO 2 ×(FiO 2 +(1-FiO 2 )/R)
Our goal was to demonstrate a significant difference in levels of IL-6 values postoperatively and before extubation between two groups. According to a pilot study (mean difference of 400 and SD≈370), with a significance level of 0.05 and a power of 80%, the calculated sample size in each group was 15 patients. We compared variables between two groups with Student's t-test, chi-square test or Fisher's exact test according to the variables.
Repeated measurement analysis of variance was applied to evaluate the effect of time and intervention simultaneously on IL-6 and (A-a) DO 2 . Statistical analysis was performed using SPSS software version 16 (SPSS, Inc., Chicago, IL, USA). P value less than 0.05 was assumed significant.
RESULTS
The patients' characteristics are depicted (Table 1 ). There were no significant differences in basic characteristics. Duration of anaesthesia, thoracotomy and operation, blood loss volume during operation, administered fluids, the lowest systolic and diastolic blood pressures, preoperative haemoglobin, preand postoperative VC and FEV 1 and duration of intubation were also comparable between the two groups. However, patients in the PGE 1 group were discharged significantly earlier from the ICU and hospital (P=0.04 and 0.03, respectively).
no PGE 1 related haemodynamic complications requiring an infusion of dopamine or cessation of the PGE 1 infusion were encountered and blood loss was not increased in the PGE 1 group.
Two patients in the control group were readmitted to the ICU because of cardiopulmonary complications, compared to none in the PGE 1 group. One patient was intubated after readmission to ICU because of respiratory distress and pulmonary oedema associated with myocardial infarction. This patient died four days after readmission to ICU. The other patient was readmitted to ICU for one day because of respiratory distress, but did not require intubation. All other patients had an uneventful postoperative course. P a O 2 (mmHg) and (A-a) DO 2 (mmHg) results are shown in Table 2 . In PGE 1 group the (A-a) DO 2 (mmHg) was significantly lower after operation.
As shown in Table 3 , serum levels of IL-6 were significantly higher in the control group.
There were no significant differences in serum levels of IL-6 in the two patients with pulmonary complications in comparison with others.
DISCUSSIOn
In this study, we demonstrated that postoperative IL-6 levels were significantly lower and oxygenation was better in the PGE 1 group compared to placebo. Patients in the PGE 1 group were discharged earlier from the ICU and hospital.
In major operations, surgical stress evokes a metabolic and systemic inflammatory response 22 , which, if excessive, may affect the ability of the host to respond to immunologic challenges and secondary immunodeficiency might occur 23 . Prevention of unrestrained inflammatory responses may attenuate the secondary immunodeficiency and prevent the multi-organ dysfunction syndrome 24, 25 . 26 , shortens the duration of systemic inflammatory response syndrome and also attenuates the severity of systemic inflammatory response syndrome after oesophagectomy 21 . Protection of organs against ischaemia reperfusion injuries 27 , amplification of anti-platelet fibrinolytic activity, inhibition of platelet and leukocyte aggregation 28, 29 , cytoprotection of hepatocytes [18] [19] [20] , increase in cardiac output and oxygen delivery 30 and smooth muscle relaxation 31, 32 are other effects that have been shown.
In our study, IL-6 levels were significantly lower in the PGE 1 group postoperatively and on the day after surgery. no differences were detected in white blood cells between the groups. nakazawa et al 9 showed that PGE 1 attenuated the increase in IL-6 compared to placebo. Interleukin-6 production from airway epithelial cells increased after transthoracic oesophagectomy 10 . As an anti-inflammatory factor, PGE 1 may modify immune response such as release of IL-6.
In this study we evaluated pulmonary function serially with arterial blood gases and changes in FEV 1 and VC. There were no significant differences in FEV 1 or VC. However, we found lower (A-a) DO 2 in the PGE 1 group in the postoperative period, as has been previously reported by others 9 . Uncontrolled inflammation, due to systemic inflammatory response to trauma of surgery or local inflammatory reactions after direct trauma to the lung in oesophagectomy via thoracotomy, may be reduced by PGE 1 . In a model of vascular lung injury in anaesthetised sheep, Gee et al 33 showed less increase in vascular permeability with the administration of PGE 1 . nakazawa et al 9 suggested that the increase in extravascular lung water during surgery was reduced by PGE 1 , and thus oxygenation was better after surgery. nevertheless, there are reports that do not support the beneficial effects of PGE 1 on postoperative oxygenation 34 . Furthermore, in both our groups P a O 2 was within an acceptable range and A-a gradients were low. The clinical significance of these findings may therefore be doubtful.
A shorter duration of ICU and postoperative hospital stay was one of the main findings in this study. Although Oda et al 21 showed an earlier hospital discharge of nearly nine days in oesophagectomy patients who received infusion of PGE 1 , this was not statistically significant. However, they concluded that all positive effects of PGE 1 culminate in fewer postoperative complications and improved outcome in these patients. Two reports on liver transplantation have shown that PGE 1 decreases postoperative morbidity and shortens the hospital stay 35, 36 . Unfortunately in our study, despite randomisation, we found that some of the basic characteristics such as age, gender, smoking and duration of procedures were not similar between the two groups ( Table 1) . Although the differences were small and were not statistically significant, cumulatively they could have exerted an effect. We also had insufficient power to compare outcomes 40 . More importantly, we cannot relate the increased ICU stay and hospital length of stay to pulmonary complications. Therefore, we cannot make firm conclusions about the effect of PGE 1 on ICU or hospital stay. The same applies to the incidence of postoperative complications.
In the PGE 1 group, none of the main complications of PGE 1 , such as significant hypotension or increased blood loss, occurred. Although PGE 1 is a known vasodilator, no significant hypotension or haemodynamic instability has been reported 9, 21 .
Others have reported only a slight decrease in arterial pressure with these low doses of PGE 1 34 . Severe falls in blood pressure may occur with larger doses of PGE 1 37 . Prostaglandin E 1 prevented the decline in platelet count following orthotopic liver transplantation 38 , but it caused a decrease in a platelet count in patients receiving massive blood transfusions 39 . An antiplatelet action of PGE 1 was previously reported, but a significant increase in blood loss or coagulopathy has not been reported in similar studies 9, 21 .
In this study, we infused PGE 1 only during operation, as several studies had done previously. Continuing the infusion of PGE 1 into the postoperative period could be more effective. Continuing infusion of PGE 1 postoperatively has been reported previously 21 , but in a significant number of studies the infusion of PGE 1 has been restricted to the intraoperative period 9, 34, 41, 42 . The effects of PGE 1 on the inflammatory system, whether given intraoperatively or continuing postoperatively, have been similar, but there has been no study comparing the effects of PGE 1 intraoperatively only with intraoperatively plus postoperatively. Moreover, PGE 1 is expensive and we were economically constrained to limit its infusion to the intraoperative period only. The ideal dose and duration of PGE 1 infusion are areas that require more research.
